These novel vaccines are utilizing a self-amplifying messenger RNA (sa-mRNA) vaccine platform. Study data was reported at the ESWI Influenza Conference in Spain.

Long-term follow-up of DAA treatment of HCV infection after liver transplant shows persistent improvement in hepatic function, fibrosis, and survival rate.

There are a number of innovative, virus-targeting agents in development to treat hepatitis C (HCV) and prevent the virus.

Antimicrobials such as clindamycin, cephalosporins, penicillins, and fluoroquinolones have been linked with causing C diff infection in prior research.

Hurricane season is accompanied by an uptick in infectious diseases associated with environmental and water exposures.

A study found variations in treatment initiation, especially showing differences within certain populations, ages, and those with a background of injection drug use.

In this week's news: A CDC committee recommends the updated COVID-19 vaccines; the cost of misinformation during the pandemic; and India is dealing with a Nipah virus outbreak.

Those with certain comorbidities, including peptic ulcer disease and renal failure, were at additional risk of developing C diff infection.

The zoonotic virus has claimed 2 lives as Indian officials work to identify potential contacts and get the virus under control.

A global review demonstrates the potential depth of the impact of the COVID-19 pandemic on ongoing immunization delay and skepticism.

The federal agency says infants of a certain age should receive this monoclonal antibody to protect against the virus.

Several trial participants experienced concerning hepatobiliary events.

The interim analysis of its phase 3 study shows the company’s mRNA-1010 vaccine was efficacious against all 4 A and B influenza strains.

The federal agency’s Advisory Committee on Immunization Practices (ACIP) recommendation was to authorize and approve the updated 2023-2024 (monovalent, XBB containing) COVID-19 vaccines for persons 6 months of age and older.

Misinformation created unnecessary hospitalizations and mortality and demonstrated the chasm in public health communication.

The agency specified which age groups the vaccine is approved for and which are authorized to use them, paving the way for fall vaccinations to take place.

This new program from the federal agency can be viewed as a useful starting point for the development and assessment tool for sepsis programs with more granularity required.

The federal agency’s reports shows decreases in both hepatitis A and B, but hepatitis C saw a significant increase during 2021. However, the investigators note the pandemic may have impacted statistics and progress towards goals.

Learn more about how hospitalizations due to alcohol-associated hepatitis increased during the pandemic; the next installment in our ongoing RSV series; developing a product for a potential functional cure of hepatitis B; and an investigational vaccine being studied in a challenge trial for norovirus.

Through policy and fostering innovation, the Biotechnology Innovation Organization (BIO) is working towards reducing antimicrobial resistance (AMR).

The investigational vaccine was studied in a challenge trial and has a novel modality in that it is delivered as a monovalent oral tablet.

Patient advocate Ella Balasa has been living with cystic fibrosis her whole life. She experienced a multidrug resistant infection in 2019 and is speaking about her personal experiences at the World AMR Congress reminding people about the need to improve the antibiotic development paradigm.

Biotech company is developing a product for a potential functional cure of the virus.

Due to increased RSV activity in the southeast United States, the CDC has issued an official Health Alert Network Health Advisory. The federal agency recommends clinicians prepare to implement recently FDA-approved prevention methods.

The Escherichia coli O157:H7 strain is linked to leafy greens–associated outbreaks over a multi-year period.